The global antibody production market size is anticipated to reach USD 42.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.92% from 2023 to 2030. Due to the rising incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, as well as the increased need for therapeutic antibodies the antibody production market is anticipated a significant growth.
Nearly half of all R&D programs related to monoclonal antibodies are allocated for cancer treatment. The focused approach of monoclonal antibodies has transformed cancer treatment by minimizing adverse effects and enhancing patient outcomes. Nevertheless, further research and development are crucial to maximize the effectiveness of antibodies in treating cancer. The market for antibody production is anticipated to experience growth due to the escalated investment in research and development activities, particularly in cancer treatment. Moreover, the demand for personalized medicine, which seeks to offer customized treatments based on an individual's genetic composition, lifestyle, and environmental influences, is anticipated to boost the antibody production market's growth.
The antibody production market was greatly influenced by the COVID-19 pandemic due to the increasing popularity of common laboratory tests like immunohistochemistry, cell imaging, and western blot analysis for diagnosis. Additionally, with the urgent need for therapeutic antibodies and vaccines to combat the virus, there has been a surge in demand for antibody production services. However, disruptions in the global supply chain and manufacturing processes caused by lockdowns, travel restrictions, and workforce shortages have posed significant challenges to the market's growth. Despite the challenges, the antibody production market has demonstrated resilience, and many companies have adapted their operations to continue serving customers during the pandemic.
Furthermore, the antibody production market is expected to grow due to the increasing demand for personalized medicine, which aims to provide tailored treatments based on an individual's genetic makeup, lifestyle, and environmental factors. Monoclonal antibodies are essential tools in personalized medicine, as they can be designed to target specific disease-causing proteins or cells. The growing demand for personalized medicine is expected to further drive the growth of the antibody production market. Additionally, the rise in the approval of antibodies for the treatment of cancer and various diseases is also contributing to market growth, as demonstrated by the U.S. FDA's emergency use authorization (EUA) for a monoclonal antibody, bebtelovimab, which retains activity against the omicron variant and is used for the treatment of COVID-19.
Request a free sample copy or view report summary: Antibody Production Market Report
Based on product, the consumables segment dominated in terms of the revenue share of 55.93% in 2022. This is attributed to growing demand for antibodies for study, diagnostics, and therapeutics, which has steered to a corresponding rise in the demand for consumables
Based on process, the downstream segment dominated in terms of the revenue share of 67.04% in 2022 owing to the various technological advancements supporting the downstream process to maintain efficiency, thus, fueling innovations in bio-manufacturing, and hence, increasing the demand for the process in the antibody production market
In 2022, North America dominated with a revenue share of 38.29%, owing to the rising investments in drug discovery, growing developments in biopharmaceutical research, and the presence of major key players are anticipated to drive the growth of the antibody production market in this region
Asia Pacific accounted for the fastest-growing region with a CAGR of 16.13% from 2023 to 2030. The growing investments in R&D activities and the increasing prevalence of chronic diseases are driving the rising demand for the antibody production market in this region
Based on type, the monoclonal antibodies segment dominated in terms of the revenue share of 63.25% in 2022 owing to the growing demand for biologics, primarily due to the increasing incidence of chronic diseases like cancer, and cardiovascular diseases, among others. Thus, increasing the demand for the monoclonal antibodies in the market.
Based on end use, the pharmaceutical and biotechnology companies segment dominates in terms of the revenue share of 55.06% in 2022. The expanding use of antibodies in the production processes of biopharmaceutical companies is considered one of the primary factors driving the growth of this segment
Grand View Research has segmented the global antibody production market based on product, process, type, end-use, and region:
Antibody Production Product Outlook (Revenue, USD Million, 2018 - 2030)
Instruments
Bioreactors
Multi-use Bioreactors
Single-use Bioreactors
Chromatography Systems
Filtration Systems
Consumables
Media
Buffers and Reagents
Chromatography Resins and Columns
Filtration Consumables and Accessories
Others
Software
Antibody Production Process Outlook (Revenue, USD Million, 2018 - 2030)
Upstream Processing
Downstream Processing
Antibody Production Type Outlook (Revenue, USD Million, 2018 - 2030)
Monoclonal Antibody
Polyclonal Antibody
Antibody Production End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical and Biotechnology Companies
Research Laboratories
CROs and CDMOs
Antibody Production Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Antibody Production Market
Illumina, Inc.
Thermo Fisher Scientific, Inc.
Pacific Biosciences of California, Inc.
BGI
QIAGEN
Agilent Technologies
PerkinElmer, Inc.
ProPhase Labs, Inc. (Nebula Genomics)
Psomagen
Azenta US, Inc.
"The quality of research they have done for us has been excellent..."